Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progress...
Enregistré dans:
Auteurs principaux: | Raj Kumar Mongre, Chandra Bhushan Mishra, Arvind Kumar Shukla, Amresh Prakash, Samil Jung, Md Ashraf-Uz-Zaman, Myeong-Sok Lee |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f7e4e2d1c4f14ffe8d65c0a026304786 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
par: Sareshma Sudhesh Dev, et autres
Publié: (2021) -
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
par: Paula Aldaz, et autres
Publié: (2021) -
Quo vadis
par: Sienkiwicz, Enrique -
Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <italic toggle="yes">Candida</italic> Species
par: Paige E. Negoro, et autres
Publié: (2020) -
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
par: Yundeok Kim, et autres
Publié: (2021)